From Perth to the Pentagon: Orthocell Unlocks Access to 221 U.S. Military Hospitals

Key Highlights:

• Orthocell gains approval across 221 U.S. military and VA hospitals
• Remplir nerve repair device enters high-value defence healthcare system
• Existing U.S. distributor network across 17 states to drive rollout
• Clinical validation strengthened through real-world use in Ukraine
• Shares surge nearly 25% on breakthrough announcement
  
   

Orthocell Limited surged 24.14% to $1.08 after announcing approval to supply its Remplir nerve repair device across the United States Department of Defence and Veterans Affairs hospital networks.

The approval opens the door to approximately 221 institutions, including 51 military hospitals and 170 Veterans Affairs medical centres, marking a major step forward in the company’s U.S. expansion strategy. 

Source: MarketIndex 

A Breakthrough Into the World’s Toughest System

Breaking into the U.S. military healthcare system is no small feat.

The Department of Defence and Veterans Affairs networks are known for their rigorous procurement standards, particularly for products used in trauma and surgical repair.

Remplir, the company’s flagship nerve repair device, is now cleared to be used in environments where injuries are often complex, high-risk, and time-critical.

Managing Director Paul Anderson described the milestone as a turning point:

“Securing access to the U.S. Department of Defence and Veterans Affairs hospital networks is a significant milestone for Orthocell and a major step forward in our U.S. commercial strategy.” 

He added that the approval allows the company to directly engage with military and VA surgeons treating complex nerve injuries and accelerate adoption across key institutions.

Scaling Up With a Ready-Made Network

Unlike early-stage biotech rollouts, Orthocell is not starting from scratch.

The company already has a distributor network covering 17 U.S. states, which will now be leveraged to target surgeons within military and VA systems. 

This creates a clear pathway for rapid commercialisation.

Orthocell has also secured 32 Value Analysis Committee approvals, providing access to more than 115 hospitals, with a further 57 applications currently under review.

The military network adds a powerful new channel on top of an already expanding footprint.

Battlefield Validation Adds Weight

One of the more compelling aspects of the announcement lies outside traditional clinical trials.

Remplir has already been used in 23 surgical procedures on injured soldiers in Ukraine, across both primary and secondary nerve repair applications. 

In military healthcare, products must perform under pressure, often in unpredictable and resource-constrained environments.

Orthocell highlighted that Remplir’s portability, ease of use, and effectiveness in treating traumatic injuries make it particularly suited for defence applications.

This kind of battlefield validation adds credibility that goes beyond laboratory data.

Industry Context: Defence Meets Biotech

The timing of this breakthrough is notable.

Global defence spending is rising, and with it, investment in advanced medical technologies designed to improve survival and recovery outcomes for soldiers.

At the same time, regenerative medicine is gaining traction as a key frontier in healthcare, particularly for repairing nerve, tendon, and tissue damage.

Orthocell sits at the intersection of these trends.

By entering the U.S. military healthcare system, the company is positioning itself within a high-value, recurring demand environment where innovation is not just encouraged but required.

Market Reaction and Momentum

The market’s response reflects the scale of the opportunity.

Orthocell’s near 25% share price jump signals growing confidence in its ability to convert access into revenue.

While the company’s one-year return remains negative, this announcement shifts the narrative toward growth and commercial traction.

With a market capitalisation of around $294 million, the company now has exposure to one of the largest healthcare systems in the world.